1.Newman, L et al. (2015) Global estimates of the prevalence and incidence of four curable sexually transmitted infections in 2012 based on systematic review and global reporting. PLoS ONE 10, 1–17.
2.Ohnishi, M et al. (2011) Is Neisseria gonorrhoeae initiating a future era of untreatable gonorrhea? Detailed characterization of the first strain with high-level resistance to ceftriaxone. Antimicrobial Agents and Chemotherapy 55, 3538–3545.
3.Unemo, M et al. (2012) High-level cefixime- and ceftriaxone-resistant Neisseria gonorrhoeae in France: novel penA mosaic allele in a successful international clone causes treatment failure. Antimicrobial Agents and Chemotherapy 56, 1273–1280.
4.Carnicer-Pont, D et al. (2012) First cases of Neisseria gonorrhoeae resistant to ceftriaxone in Catalonia Spain, May 2011. Enfermedades Infecciosas y Microbiología Clínica 30, 218–219.
5.Bignell, C and Unemo, M (2013) 2012 European guideline on the diagnosis and treatment of gonorrhoea in adults. International Journal of STD and AIDS 24, 85–92.
6.Workowski, KA et al. (2015) Sexually transmitted diseases treatment guidelines, 2015. Morbidity and Mortality Weekly Report Recommendations and Reports 64, 1–137.
9.Fifer, H et al. (2016) Failure of dual antimicrobial therapy in treatment of gonorrhea. New England Journal of Medicine 374, 2504–2506.
10.Eyre, DW et al. (2018) Gonorrhoea treatment failure caused by a Neisseria gonorrhoeae strain with combined ceftriaxone and high-level azithromycin resistance, England, February 2018. Eurosurveillance 23, 1800323.
11.Eyre, DW et al. (2019) Detection in the United Kingdom of the Neisseria gonorrhoeae FC428 clone, with ceftriaxone resistance and intermediate resistance to azithromycin, October to December 2018. Eurosurveillance 24, 1900147.
12.Golparian, D et al. (2018) Multidrug-resistant Neisseria gonorrhoeae isolate, belonging to the internationally spreading Japanese FC428 clone, with ceftriaxone resistance and intermediate resistance to azithromycin, Ireland, August 2018. Eurosurveillance 23, 1800617.
13.World Health Organization (2012) Global Action Plan to Control the Spread and Impact of Antimicrobial Resistance in Neisseria gonorrhoeae. Geneva: World Health Organization. http://www.who.int/iris/handle/10665/44863 ( 3 February 2019).
16.Cole, MJ et al. (2017) Overall low extended-spectrum cephalosporin resistance but high azithromycin resistance in Neisseria gonorrhoeae in 24 European countries, 2015. BMC Infectious Diseases 17, 617.
17.The European Committee on Antimicrobial Susceptibility Testing (2016) .
18.Clinical Laboratory Standards Institute (2016) Performance Standards for Antimicrobial Susceptibility Testing, 26th Edn. . Wayne, PA: Clinical and Laboratory Standards Institute.
19.Martin, IM et al. (2014) Rapid sequence-based identification of gonococcal transmission clusters in a large metropolitan area. Journal of Infectious Diseases 189, 1497–1505.
20.Chisholm, SA et al. (2013) Molecular epidemiological typing within the European gonococcal antimicrobial resistance surveillance programme reveals predominance of a multidrug resistant clone. Eurosurveillance 18, 1–10.
21.Kumar, S, Stecher, G and Tamura, K (2016) MEGA7: molecular evolutionary genetics analysis version 7.0 for bigger datasets. Molecular Biology and Evolution 33, 1870–1874.
22.Serra-Pladevall, J et al. (2017) Differences in Neisseria gonorrhoeae population structure and antimicrobial resistance pattern between men who have sex with men and heterosexuals. Epidemiology and Infection 145, 379–385.
23.Fuertes, I et al. (2018) Risk factors for antimicrobial-resistant Neisseria gonorrhoeae and characteristics of patients infected with gonorrhea. Enfermedades Infecciosas y Microbiología Clínica 36, 194–195.
24.Cobo, F, Cabezas-Fernández, MT and Cabeza-Barrera, MI (2016) Antimicrobial susceptibility and typing of Neisseria gonorrhoeae strains from Southern Spain, 2012–2014. Enfermedades Infecciosas y Microbiología Clínica 34, 3–7.
25.Serra-Pladevall, J et al. (2016) Neisseria gonorrhoeae antimicrobial susceptibility in Barcelona: penA, ponA, mtrR, and porB mutations and NG-MAST sequence types associated with decreased susceptibility to cephalosporins. European Journal of Clinical Microbiology and Infectious Diseases 35, 1549–1556.
26.Gratrix, J et al. (2016) A retrospective review of treatment failures using azithromycin and doxycycline in the treatment of rectal chlamydia infections in women and men who have sex with men. Sexually Transmitted Diseases 43, 110–112.
27.Kissinger, P et al. (2016) Azithromycin treatment failure for Chlamydia trachomatis among heterosexual men with nongonococcal urethritis. Sexually Transmitted Diseases 43, 599–602.
28.Manhart, LE et al. (2015) Efficacy of antimicrobial therapy for Mycoplasma genitalium infections. Clinical Infectious Diseases 61, S802–S817.
29.Brown, LB et al. (2010) Neisseria gonorrhoeae antimicrobial susceptibility in Lilongwe, Malawi, 2007. Sexually Transmitted Diseases 37, 169–172.
30.Brittain, C et al. (2016) Gentamicin versus ceftriaxone for the treatment of gonorrhoea (G-TOG trial): study protocol for a randomised trial. Trials 17, 558.
31.Kirkcaldy, RD et al. (2014) The efficacy and safety of gentamicin plus azithromycin and gemifloxacin plus azithromycin as treatment of uncomplicated gonorrhea. Clinical Infectious Diseases 59, 1083–1091.
32.Dowell, D and Kirkcaldy, RD (2012) Effectiveness of gentamicin for gonorrhoea treatment: a systematic review. Sexually Transmitted Infections 88, 589–594.
33.Daly, CC et al. (1997) Development of an antimicrobial susceptibility surveillance system for Neisseria gonorrhoeae in Malawi: Comparison of methods. Journal of Clinical Microbiology 35, 2985–2988.
35.Regnath, T, Mertes, T and Ignatius, R (2016) Antimicrobial resistance of Neisseria gonorrhoeae isolates in south-west Germany, 2004 to 2015: increasing minimal inhibitory concentrations of tetracycline but no resistance to third-generation cephalosporins. Eurosurveillance 21, 1–7.
36.Unemo, M and Shafer, WM (2014) Antimicrobial resistance in Neisseria gonorrhoeae in the 21st century: past, evolution, and future. Clinical Microbiology Reviews 27, 587–613.
37.Cole, MJ et al. (2014) Risk factors for antimicrobial-resistant Neisseria gonorrhoeae in Europe. Sexually Transmitted Diseases 41, 723–729.
38.Koedijk, FD et al. (2010) Increasing trend in gonococcal resistance to ciprofloxacin in The Netherlands, 2006–8. Sexually Transmitted Infections 86, 41–45.
39.Lewis, DA (2013) The role of core groups in the emergence and dissemination of antimicrobial-resistant N. gonorrhoeae. Sexually Transmitted Infections 89(suppl. 4), 47–51.